Pharmacokinetics and excretion of (14)C-omacetaxine in patients with advanced solid tumors

about

Pharmacokinetics and excretion of (14)C-omacetaxine in patients with advanced solid tumors

Item

http://www.wikidata.org/entity/Q37222797

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 25 May 2016

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Pharmacokinetics and excretion ...... nts with advanced solid tumors

@en

Pharmacokinetics and excretion of

@nl

type

Item

label

Pharmacokinetics and excretion ...... nts with advanced solid tumors

@en

Pharmacokinetics and excretion of

@nl

prefLabel

Pharmacokinetics and excretion ...... nts with advanced solid tumors

@en

Pharmacokinetics and excretion of

@nl

P1476

Pharmacokinetics and excretion ...... nts with advanced solid tumors

@en

P2093

Alwin D R Huitema

http://www.w3.org/2001/XMLSchema#string

Cynthia M Nijenhuis

http://www.w3.org/2001/XMLSchema#string

Diane Hershock

http://www.w3.org/2001/XMLSchema#string

Edward Hellriegel

http://www.w3.org/2001/XMLSchema#string

Hilde Rosing

http://www.w3.org/2001/XMLSchema#string

Jan H M Schellens

http://www.w3.org/2001/XMLSchema#string

Jos H Beijnen

http://www.w3.org/2001/XMLSchema#string

Laura Rabinovich-Guilatt

http://www.w3.org/2001/XMLSchema#string

Luc Lucas

http://www.w3.org/2001/XMLSchema#string

Marja Mergui-Roelvink

http://www.w3.org/2001/XMLSchema#string

P2860

U2504 Determines the Species Specificity of the A-Site Cleft Antibiotics:

Sequential homoharringtonine and interferon-alpha in the treatment of early chronic phase chronic myelogenous leukemia.

Pharmacokinetic study of omacetaxine mepesuccinate administered subcutaneously to patients with advanced solid and hematologic tumors

Phase II study of low-dose continuous infusion homoharringtonine in refractory acute myelogenous leukemia.

Homoharringtonine therapy induces responses in patients with chronic myelogenous leukemia in late chronic phase.

Homoharringtonine: history, current research, and future direction.

Mass balance studies, with a focus on anticancer drugs.

New insights into the pathophysiology of chronic myeloid leukemia and imatinib resistance.

A phase II open-label study of the intravenous administration of homoharringtonine in the treatment of myelodysplastic syndrome

Issues of imatinib and pregnancy outcome.

P2888

s10637-016-0360-9

P304

565-574

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S10637-016-0360-9

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-05-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27221729

http://www.w3.org/2001/XMLSchema#string

P932

5007276

http://www.w3.org/2001/XMLSchema#string